Provided by Tiger Trade Technology Pte. Ltd.

Molecular Partners AG

4.13
-0.2699-6.13%
Volume:2K
Turnover:8.58K
Market Cap:154.46M
PE:-2.13
High:4.35
Open:4.35
Low:4.13
Close:4.40
52wk High:5.36
52wk Low:3.53
Shares:37.40M
Float Shares:19.92M
Volume Ratio:1.72
T/O Rate:0.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9371
EPS(LYR):-2.0808
ROE:-59.01%
ROA:-28.82%
PB:1.81
PE(LYR):-1.98

Loading ...

Molecular Partners AG Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Yesterday

Molecular Partners Q2 EPS $(0.89) Misses $(0.45) Estimate

Benzinga Earnings
·
Yesterday

Molecular Partners Reports H1 2026 Financial Results With Net Loss Narrowing To CHF 26.7M From CHF 37.2M YoY, And Cash Position Of CHF 67.9M

Benzinga Earnings
·
Yesterday

Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study

GlobeNewswire
·
Yesterday

Molecular Partners AG Expected to Post a Loss of 35 Rappen a Share - Earnings Preview

Reuters
·
Aug 21

Molecular Partners doses first patients in MP0317 combination study

TIPRANKS
·
Jul 16

Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy

MT Newswires Live
·
Jul 16

Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma

GlobeNewswire
·
Jul 16

Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference

GlobeNewswire
·
Jul 15

LifeSci Capital Sticks to Their Buy Rating for Molecular Partners (MOLN)

TIPRANKS
·
Jul 11

Molecular Partners Makes Progress on Radiotherapy Cancer Candidates

MT Newswires Live
·
Jul 06

Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics

GlobeNewswire
·
Jul 06

Molecular Partners, Orano Med doses first patient in MP0712 study

TIPRANKS
·
Jul 02

Molecular Partners Doses First Patients in Lung Cancer Trial

MT Newswires Live
·
Jul 02

Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712

GlobeNewswire
·
Jul 02

Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Molecular Partners (MOLN) and Park Dental Partners, Inc. (PARK)

TIPRANKS
·
Jun 05

Molecular Partners to hold trial-in-progress presentations on Phase 1/2a study

TIPRANKS
·
Jun 01

Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1

GlobeNewswire
·
May 30

Molecular Partners to Present at TD Cowen’s 7th Annual Oncology Innovation Summit

GlobeNewswire
·
May 27

Analysts Are Bullish on Top Healthcare Stocks: Molecular Partners (MOLN), Enliven Therapeutics (ELVN)

TIPRANKS
·
May 16